Paper32036613
Tafenoquine for the radical cure and prevention of malaria: the importance of testing for G6PD deficiency.
Commons RJ and 2 others. Med J Aust, 2020. Cited by 31 papers, by iCite.
Cite this record
ConductScience Library. Tafenoquine for the radical cure and prevention of malaria: the importance of testing for G6PD deficiency. Papers, record 32036613. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32036613
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Tafenoquine for the radical cure and prevention of malaria: the importance of testing for G6PD deficiency.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Aminoquinolines | Major topic |
| Antimalarials | Major topic |
| Glucosephosphate Dehydrogenase Deficiency | Major topic |
| Malaria | Major topic |
| Female | |
| Humans | |
| Male | |
| Practice Guidelines as Topic | |
| Primaquine |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 200909/Z/16/Z | Wellcome Trust | United Kingdom | PubMed |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT05203744 | Escalating Monthly Doses of Tafenoquine in Healthy Volunteers | Background |
Source ClinicalTrials.gov
References13
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30941413 | Tafenoquine and G6PD: a primer for clinicians. | J Travel Med | 2019 | https://conductscience.org/library/papers/30941413 | PubMed |
| 2 | 30350771 | Evaluation of a Novel Quantitative Test for Glucose-6-Phosphate Dehydrogenase Deficiency: Bringing Quantitative Testing for Glucose-6-Phosphate Dehydrogenase Deficiency Closer to the Patient. | Am J Trop Med Hyg | 2019 | https://conductscience.org/library/papers/30350771 | PubMed |
| 3 | 9598455 | First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial. | Am J Trop Med Hyg | 1998 | https://conductscience.org/library/papers/9598455 | PubMed |
| 4 | 29499733 | Primaquine-induced haemolysis in females heterozygous for G6PD deficiency. | Malar J | 2018 | https://conductscience.org/library/papers/29499733 | PubMed |
| 5 | 29738562 | Validation of the quantitative point-of-care CareStart biosensor for assessment of G6PD activity in venous blood. | PLoS One | 2018 | https://conductscience.org/library/papers/29738562 | PubMed |
| 6 | 22293322 | Glucose-6-phosphate dehydrogenase (G6PD) mutations database: review of the "old" and update of the new mutations. | Blood Cells Mol Dis | 2012 | https://conductscience.org/library/papers/22293322 | PubMed |
| 7 | 22968164 | Primaquine toxicity forestalls effective therapeutic management of the endemic malarias. | Int J Parasitol | 2012 | https://conductscience.org/library/papers/22968164 | PubMed |
| 8 | 28893237 | Methods for the field evaluation of quantitative G6PD diagnostics: a review. | Malar J | 2017 | https://conductscience.org/library/papers/28893237 | PubMed |
| 9 | 30650326 | Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. | N Engl J Med | 2019 | https://conductscience.org/library/papers/30650326 | PubMed |
| 10 | 30650322 | Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria. | N Engl J Med | 2019 | https://conductscience.org/library/papers/30650322 | PubMed |
| 11 | 24360369 | Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. | Lancet | 2014 | https://conductscience.org/library/papers/24360369 | PubMed |
| 12 | 30380095 | Tafenoquine for travelers' malaria: evidence, rationale and recommendations. | J Travel Med | 2018 | https://conductscience.org/library/papers/30380095 | PubMed |
| 13 | 11700577 | A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria. | Clin Infect Dis | 2001 | https://conductscience.org/library/papers/11700577 | PubMed |
Cited by29
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 31 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42373213 | Risk perceptions of high-dose primaquine and tafenoquine among Plasmodium vivax malaria stakeholders in Ethiopia: a qualitative study. | BMJ Glob Health | 2026 | https://conductscience.org/library/papers/42373213 | PubMed |
| 41593688 | Tafenoquine succinate inhibits the growth of the equine piroplasmosis hemoparasites Theileria equi and Babesia caballi. | Parasit Vectors | 2026 | https://conductscience.org/library/papers/41593688 | PubMed |
| 41484619 | Moving towards high-dose primaquine or single-dose tafenoquine for Plasmodium vivax treatment in Cambodia: a meeting report from dissemination of results of the EFFORT trial to stakeholders. | Malar J | 2026 | https://conductscience.org/library/papers/41484619 | PubMed |
| 41029685 | Perceptions of shorter radical cure Plasmodium vivax treatment regimens and their implementation: a qualitative study among stakeholders in Cambodia. | Malar J | 2025 | https://conductscience.org/library/papers/41029685 | PubMed |
| 40525408 | Cethromycin pharmacokinetics and pharmacodynamics for single dose cure of Plasmodium berghei liver stages. | Antimicrob Agents Chemother | 2025 | https://conductscience.org/library/papers/40525408 | PubMed |
| 40437509 | Co-design of a routine clinical review to improve the safety of high dose radical cure treatment for Plasmodium vivax malaria: findings from Cambodia and Ethiopia. | Malar J | 2025 | https://conductscience.org/library/papers/40437509 | PubMed |
| 40387615 | Integrated Phenotypic and Genotypic Approaches for Accurate Diagnosis of G6PD Deficiency: Implications for Drug Safety in Thailand. | Pharmacol Res Perspect | 2025 | https://conductscience.org/library/papers/40387615 | PubMed |
| 40038735 | In vitro and in silico evaluation of synthetic compounds derived from bi-triazoles against asexual and sexual forms of Plasmodium falciparum. | Malar J | 2025 | https://conductscience.org/library/papers/40038735 | PubMed |
| 38699793 | Exploring Appropriate Reference Intervals and Clinical Decision Limits for Glucose-6-Phosphate Dehydrogenase Activity in Individuals From Guangzhou, China. | Ann Lab Med | 2024 | https://conductscience.org/library/papers/38699793 | PubMed |
| 38241389 | Field assessment of the operating procedures of a semi-quantitative G6PD Biosensor to improve repeatability of routine testing. | PLoS One | 2024 | https://conductscience.org/library/papers/38241389 | PubMed |
| 37971260 | Cytochrome P450 2D6 profiles and anti-relapse efficacy of tafenoquine against Plasmodium vivax in Australian Defence Force personnel. | Antimicrob Agents Chemother | 2023 | https://conductscience.org/library/papers/37971260 | PubMed |
| 37817240 | Effect of adherence to primaquine on the risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. | Malar J | 2023 | https://conductscience.org/library/papers/37817240 | PubMed |
| 37388931 | Population screening for glucose-6-phosphate dehydrogenase deficiency using quantitative point-of-care tests: a systematic review. | Front Genet | 2023 | https://conductscience.org/library/papers/37388931 | PubMed |
| 36378465 | Plasmodium vivax in Children: Hidden Burden and Conspicuous Challenges, a Narrative Review. | Infect Dis Ther | 2023 | https://conductscience.org/library/papers/36378465 | PubMed |
| 36339627 | Genotype-phenotype association and biochemical analyses of glucose-6-phosphate dehydrogenase variants: Implications for the hemolytic risk of using 8-aminoquinolines for radical cure. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/36339627 | PubMed |
| 34950624 | Understanding Malaria Persistence: A Mixed-Methods Study on the Effectiveness of Malaria Elimination Strategies in South-Central Vietnam. | Front Public Health | 2021 | https://conductscience.org/library/papers/34950624 | PubMed |
| 34934109 | Combined effects of double mutations on catalytic activity and structural stability contribute to clinical manifestations of glucose-6-phosphate dehydrogenase deficiency. | Sci Rep | 2021 | https://conductscience.org/library/papers/34934109 | PubMed |
| 34620901 | Probing the distinct chemosensitivity of Plasmodium vivax liver stage parasites and demonstration of 8-aminoquinoline radical cure activity in vitro. | Sci Rep | 2021 | https://conductscience.org/library/papers/34620901 | PubMed |
| 34543346 | Reference and point-of-care testing for G6PD deficiency: Blood disorder interference, contrived specimens, and fingerstick equivalence and precision. | PLoS One | 2021 | https://conductscience.org/library/papers/34543346 | PubMed |
| 34526770 | Safety and Efficacy of Tafenoquine for Plasmodium vivax Malaria Prophylaxis and Radical Cure: Overview and Perspectives. | Ther Clin Risk Manag | 2021 | https://conductscience.org/library/papers/34526770 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| G6PD | 2539 | PubTator's text mining | https://conductscience.org/library/genes/2539 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32036613
GET https://conductscience.org/api/papers/v1/32036613/cited_by?page=2